Protein Physicochemical Property Determination

Determination of physicochemical properties for protein therapeutics or other biologics, determined in line with ICH Q6B, EMA and FDA guidelines including molecular weight, isoform, electrophoretic, chromatographic and spectroscopic profiles
Determination of the physicochemical properties of a protein therapeutic allows the relevant specifications to be established. Understanding the physicochemical properties of a biologic also supports drug development and ongoing quality control. A range of methods and technology are required to determine these properties for your specific protein - the challenge is to select and adapt the most appropriate technical approaches for the product in question.
Our scientists deliver protein physicochemical property analytical programs in line with appendix 6.1.2 in the ICH Q6B guidelines: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. Our programs are designed to optimise the data required to determine or confirm identity, explore patterns of heterogeneity and demonstrate consistency in quality for the drug. We are adept at method development and conduct phase-appropriate validation of methods where required.
We apply our Total Quality Assurance expertise to developing, validating and conducting physicochemical testing programs that can expedite your protein characterisation programs, helping you to meet your development and submission milestones.
COVID-19 VACCINE OR THERAPEUTIC TESTING & DEVELOPMENT SUPPORT
IMMEDIATE QUESTION? Ask our experts now
FACTSHEET: COVID-19 Vaccine or Therapeutic Testing & Development Outsourcing
ARTICLE: Repurposing Vaccines for Intranasal Development
WEBINAR: Quality Control Strategy for Vaccine Development
WEBINAR: Repurposing Drugs for Inhaled Delivery
eBOOK: Contingency Outsourcing Solutions
Intertek Pharmaceutical Services Manchester
P.O. Box 42
Hexagon Tower
Blackley
Manchester, M9 8ZS
United Kingdom
For location use: M9 8GQ
DISCOVER MORE
Download our latest online resources
SPECIAL REPORT: Peptides Therapeutics: Designing a Science-Led, Strategic QC Program
ARTICLE: Meeting Regulatory Expectations for Biosimilar Development
WEBINAR: Monitoring Glycosylation using Site Specific Approaches
WEBINAR: Current Analytical Approaches to Biophysical Characterisation
ARTICLE: Characterisation of Bispecifics
SPECIAL REPORT: Biophysical Characterisation of Biologics
ARTICLE: mAbs - Characterising Critical Quality Attributes
ARTICLE: New Approaches to Bioassay Design
WHITE PAPER: GMP Flow Cytometry - Applications, Considerations and Challenges
ARTICLE: Significance and Challenges of Inhaled and Nasal Biologics
ARTICLE: Physicochemical Properties of Liposomal Advanced Drug Delivery Technologies
NEW! Discover our Audit Live Tool for direct access to our scheduled audits
EVENT: 2nd Annual Inhaled and Nasal Biologics/DNA Forum - REGISTRATION IS LIVE
VIDEO:EXTRACTABLES/LEACHABLES LAB TOUR - Request access
WORKSHOP: How to Build an Inhaler (RDD 2023)
PRESENTATION:E&L Strategies (3rd Annual Extractables & Leachables Conference)
TALK: Medical Device Extractables & Leachables Studies
TALK: ID and sensitivity issues during E&L studies
ARTICLE: Glycosylation Analytical Approaches for Antibody Therapeutics
APP NOTE: Rapid Determination of Low/Trace Level Benzene in Pharmaceutical Excipients and Finished Products
ARTICLE: Importance of Aligning a Pharma Audit Scope with the Correct Standard
TALK: mRNA Analytics: Capping Efficiency, Sequencing, Poly-A Tail, dsRNA